New Content  edit
Get The App!

Loading the player...
Update on JAK Inhibitor — Spleen Volume Reduction and OS interview with Srdan Verstovsek, MD, PhD, at ASH 2011
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
At the American Society of Hematology (ASH) 2011, Srdan Verstovsek, MD, PhD, discusses the results of the COMFORT I Study, which included consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups as well as overall survival advantage. Comparison of outcomes of advanced myelofibrosis patients treated with ruxolitinib to those of a historical control group is also discussed.

Accompanying this interview are two downloadable slide decks of the abstracts.